BioNTech Takes Aim at Keytruda With Potential $950M Biotheus Buy
The acquisition will give BioNTech full ownership of an investigational bispecific antibody targeting the PD-L1/VEGF-A pathways, a hot area in oncology that could potentially replace standard checkpoint inhibitors for cancer treatment.
BioNTech Takes Aim at Keytruda With Potential $950M Biotheus Buy Read More »
